Journal article
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib
Abstract
BACKGROUND: Gene amplification status of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) were analyzed and correlated with clinical outcome in patients with progressive malignant salivary glands tumors (MSGT) treated with the dual EGFR/Her2 tyrosine kinase inhibitor lapatinib.
METHODS: Fluorescence in situ hybridization (FISH) analysis for both EGFR and HER2 gene amplification was performed …
Authors
Vidal L; Tsao MS; Pond GR; Cohen EEW; Cohen RB; Chen EX; Agulnik M; Hotte S; Winquist E; Laurie S
Journal
Head & Neck, Vol. 31, No. 8, pp. 1006–1012
Publisher
Wiley
Publication Date
August 2009
DOI
10.1002/hed.21052
ISSN
1043-3074
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedBiomarkers, TumorCarcinoma, Adenoid CysticDose-Response Relationship, DrugDrug Administration ScheduleErbB ReceptorsFemaleFollow-Up StudiesGene AmplificationHumansIn Situ Hybridization, FluorescenceInfusions, IntravenousLapatinibMaleMaximum Tolerated DoseMiddle AgedNeoplasm InvasivenessNeoplasm StagingProbabilityPrognosisQuinazolinesReceptor, ErbB-2Reference ValuesSalivary Gland NeoplasmsSurvival AnalysisTreatment Outcome